Antibody recognizing folate receptors alpha and beta
US-2015343088-A1 · Dec 3, 2015 · US
Methods of use for an antimicrobial peptide
US9278121B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9278121-B2 |
| Application number | US-201313803678-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2013 |
| Priority date | Mar 14, 2013 |
| Publication date | Mar 8, 2016 |
| Grant date | Mar 8, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention encompasses methods for treating an infection and/or treating or reducing inflammation through the administration of a therapeutically effective amount of a peptide to a subject in need thereof. In some aspects, the peptide is a Helicobacter pylori -derived peptide, such as an HPA3NT3 peptide and the infection is a bacterial infection.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating an infection and infection-induced inflammation in non-immortalized cells, the method comprising topically administering a therapeutically effective amount of an HPA3NT3 peptide. 2. The method of claim 1 , wherein the non-immortalized cells are primary cells. 3. The method of claim 1 , wherein the non-immortalized cells are at least one of keratinocytes, dermal microvascular endothelial cells, corneal epithelial cells, and dermal fibroblasts. 4. The method of claim 1 , wherein the infection is a bacterial infection. 5. The method of claim 4 , wherein the bacteria causing the bacterial infection is at least one of Propionibacterium acnes, Staphylococcus aureus , or Pseudomonas aeruginosa. 6. The method of claim 5 , wherein the Pseudomonas aeruginosa bacteria are resistant to more than one antibiotic. 7. The method of claim 6 , wherein the therapeutically effective amount of HPA3NT3 peptide functions as a bactericidal agent. 8. A method of reducing expression of at least one pro-inflammatory cytokine by a non-immortalized cell, the method comprising topically administering a therapeutically effective amount of an HPA3NT3 peptide to the cell.
Assignees
Inventors
Classifications
- A61K38/164Primary
from bacteria · CPC title
Antibacterial agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9278121B2 cover?
- The present invention encompasses methods for treating an infection and/or treating or reducing inflammation through the administration of a therapeutically effective amount of a peptide to a subject in need thereof. In some aspects, the peptide is a Helicobacter pylori -derived peptide, such as an HPA3NT3 peptide and the infection is a bacterial infection.
- Who is the assignee on this patent?
- Trustees University Of Arkansas Board Of, Univ Arkansas, Chosun University
- What technology area does this patent fall under?
- Primary CPC classification A61K38/164. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).